For the Inventor, By the Inventor

Enter assignee name

New South Wales, Australia

Peptide Technology Limited

Calculating rank

USPTO Granted Patents = 14

Forward Citations = 386

Loading Chart...

Loading Chart...

24 inventors (with patents filed for the assignee):

Deborah Ann Rathjen (9 out of 24 patents)

Antonio Ferrante (5 out of 11 patents)

Roger Aston (4 out of 17 patents)

4. Alfred Poulos (3 out of 5 patents)

5. Fred Widmer (3 out of 7 patents)

6. Jurgen Michaelis (3 out of 3 patents)

7. Timothy Elliot Trigg (2 out of 8 patents)

8. Merilyn Joy Sleigh (2 out of 3 patents)

9. Paul Adam Schober (1 out of 4 patents)

10. Michael Joseph Pitt (1 out of 2 patents)

11. Thomas Alistair Robertson (1 out of 1 patent)

12. Christopher John Easton (1 out of 2 patents)

13. David James Phipps (1 out of 3 patents)

14. Douglas Kevin MacFadden (1 out of 3 patents)

15. Penelope Reed Doob (1 out of 3 patents)

14 patents: Sort by Forward Citations

1. 6416757 - Tumor necrosis factor antibodies (2002-07-09),

2. 6376688 - Modified polyunsaturated fatty acids (2002-04-23),

3. 6121237 - Neutrophil stimulating peptides (2000-09-19),

4. 5998476 - Synthetic polyunsaturated fatty acid analogues (1999-12-07),

5. 5959087 - Tumour necrosis factor binding ligands (1999-09-28),

6. 5798335 - Method for the treatment or prevention of eczema/dermatitis (1998-08-25),

7. 5795859 - Peptide which abrogates TNF and/or LPS toxicity (1998-08-18),

8. 5795858 - Treatment or prevention of Crohn's disease and/or ulcerative colitis (1998-08-18),

9. 5767156 - Polyunsaturated fatty acids and uses thereof (1998-06-16),

10. 5756449 - Peptide T and related peptides in the treatment of inflammation, (1998-05-26),

11. 5644034 - Tumour necrosis factor binding ligands (1997-07-01),

12. 5587457 - Neutrophil stimulating peptides (1996-12-24),

13. 5561110 - Method for the treatment of the complications and pathology of diabetes (1996-10-01),

14. 5545408 - Biocompatible implant for the timing of ovulation in mares (1996-08-13),

Company Overview

Peptide Technology Limited is a biotechnology company based in New South Wales, Australia, specializing in the development and manufacture of peptide-based products. The organization focuses on innovative solutions for various applications, including pharmaceuticals and research tools. With a commitment to advancing peptide synthesis and delivery technologies, Peptide Technology Limited plays a significant role in the life sciences sector, contributing to the development of therapeutics and diagnostic tools that leverage the unique properties of peptides.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

14 Patents

#15 in New South Wales

#272 in Australia

#42,384 in the World

New South Wales, Australia

Peptide Technology Limited

Forward Citations = 386

24 inventors:

Deborah Ann Rathjen (9 out of 24 patents)

Antonio Ferrante (5 out of 11 patents)

Roger Aston (4 out of 17 patents)

4. Alfred Poulos (3 out of 5 patents)

5. Fred Widmer (3 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Peptide Technology Limited. Retrieved from https://idiyas.com/company/peptide-technology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…